*4.8. Conclusions*

Our present proof-of-concept study suggests that rapid campimetry has advantages in glaucoma-screening compared to SAP. However, follow-up assessments are needed that investigate greater sample sizes of patients and healthy controls to assess the value of rapid campimetry as a screening and diagnostic tool for VF defect detection in glaucoma. In short, this method appears to be comparable to standard perimetry in the detection of central VF defects in glaucoma, and holds promise of applicability in ophthalmology as a screening and telemedicine tool.

#### **5. Patents**

European patent pending: Nr. EP21151704.0, EP21176171.3, EP21196409.3—PCT/ EP2022/050765 "Verfahren und Einrichtung zum Messen des Gesichtsfeldes einer Person".

**Author Contributions:** Conceptualization, F.H. and F.M.; methodology, F.H. and F.M.; investigation, F.H., F.M., K.O.A.-N. and C.M.; software, F.M.; writing—original draft preparation, F.H. and F.M.; writing—review and editing, F.M., K.O.A.-N., F.H.K., C.M., N.D., H.T., M.B.H. and F.H. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by funding of the German research foundation (DFG, HO2002/20-1) to MBH.

**Institutional Review Board Statement:** The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by Ethics Committee of Faculty of medicine, Otto-von-Guericke University, Magdeburg (No: 151/16).

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

**Data Availability Statement:** Upon request.

**Acknowledgments:** Dedication: to Elfriede Aulhorn (†), my (F.H.) mentor.

**Conflicts of Interest:** Fabian Müller received no support for the present manuscript but he had funding for the patenting with H & M Medical Solutions GmbH. Other authors had none. The authors declare no conflict of interest.
